Signifi cant progress has been made in the fi eld of exercise-oncology research over the past two decades. As the fi eld continues to forge ahead, it is time to refl ect on past accomplishments in order to inform and defi ne the critical unanswered questions postulated to have the largest impact on the fi eld and on clinical care. Against this background, we overview the extant literature base together with ongoing/planned studies examining the role of exercise therapy following a cancer diagnosis with a view towards identifying major gaps in the knowledge. Method . We adapted the Physical Exercise Across the Cancer Experience (PEACE) organizational framework to systematically overview published as well as ongoing studies of exercise therapy across the cancer survivorship continuum [i.e. 1) pretreatment; 2) during treatment; and 3) post-treatment]. To overview ongoing studies, we performed a systematic review of all exercise trials in adult cancer patients registered in Clinical Trials.Gov and the International Standard Randomized Controlled Trial Number Register. Results . Data from published studies provides relatively strong evidence that exercise therapy is a well-tolerated and safe adjunct therapy that can mitigate several common treatment-related side effects among cancer patients across the PEACE framework. In addition, observational studies suggest that higher levels of exercise may be associated with improved prognosis in patients with solid tumors. Regarding ongoing studies, a total of 82 independent clinical studies were identifi ed. Consistent with prior work, most ongoing studies are being conducted either during or following adjuvant therapy in women with breast cancer with exercise interventions following standard exercise prescription guidelines. Across all studies, there were a total of approximately 51 different primary endpoints; in two-thirds of studies, quality of life, fatigue, or physical functioning was the primary endpoint. Conclusion . There have been signifi cant leaps in knowledge regarding the role and effi cacy of exercise therapy in cancer survivors over the past 25 years. On the platform of this evidence base, it is now time to launch the next generation of research to ensure continued progress in this emergent fi eld. This work will continue to contribute to the ultimate goal of improving both the quantity and quality of life of persons diagnosed with cancer.
In the late 1980s, Drs. Winningham and MacVicar, two pioneer oncology nurses from The Ohio State University in the US, performed a randomized trial investigating the effi cacy of 10-weeks of intervalbased, aerobic exercise training on functional capacity, body composition, and patient reported nausea in 45 women receiving conventional adjuvant chemotherapy for operable breast cancer [1 -3] . The rationale for the trial was that adjuvant chemotherapy causes physical inactivity (deconditioning) that, in turn, results in maladaptations in several if not all organ components of the cardiovascular system ultimately leading to overt clinical symptoms/conditions. In contrast, based on the established benefi ts in other non-cancer clinical populations, aerobic exercise training may be an effective strategy to prevent the overt clinical symptoms/conditions associated with deconditioning in cancer patients. Today, a trial of this nature would be considered relatively straightforward and one likely met with enthusiasm from the oncology team, oncology patients, and their caregivers. However, in the late 1980s, testing the effi cacy of exercise training in this setting was a radical departure from the norm and in direct contrast to the standard recommendation for patients undergoing cytotoxic therapy -to rest and avoid exercise, particularly high-intensity aerobic training. This trial, however, demonstrated that interval aerobic exercise training was not only feasible, safe, and acceptable, a major fi nding unto itself, but that it also caused signifi cant improvements in aerobic capacity, body composition, and patient-reported nausea [1 -3] .
In the years immediately following publication of this landmark study, interest in the area of exerciseoncology remained limited with publication of a relatively small number of studies in the early-to-mid 1990s [4] . During this time, however, Dimeo and colleagues conducted some of the fi rst European (Germany) exercise-oncology trials, pioneering the role of exercise as supportive treatment for patients undergoing stem cell transplantation [5 -7] . For example, in 1997, Dimeo et al. [8] published an innovative study demonstrating that daily supine cycle ergometry for 30 min/daily during hospitalization after high-dose chemotherapy and stem cell transplantation, compared with usual care, was associated with signifi cant attenuation of declines in physical performance, pain, diarrhea, and shorter hospital duration. In 2001 Dr. Segal and colleagues published a large randomized controlled trial investigating the effects of supervised or home-based (selfdirected) aerobic training on physical functioning and quality of life (QOL) in 121 operable breast cancer patients during or following adjuvant therapy [9] . Similar to the fi ndings of Winningham and MacVicar [1 -3] , aerobic exercise training attenuated the decline in physical functioning in patients receiving chemotherapy and improved physical functioning in those following the completion of adjuvant therapy. Importantly, while this was the largest trial to date, it was also the fi rst to be published in the Journal of Clinical Oncology , the offi cial journal of the American Society of Clinical Oncology (ASCO); hence, this publication immediately elevated the credibility of exercise training as a supportive care intervention in the oncology setting. The work of Segal and colleagues, in conjunction with later publications [4] , also coincided with the increasing recognition given to the importance of cancer survivorship research and practice (e.g. the US National Cancer Institute ' s Offi ce of Cancer Survivorship had been launched in 1996). Over the past decade, exercise therapy has emerged as an important factor to enhance cancer survivorship outcomes, with this research being conducted across a broad range of disciplines from several different continents [10] . This increased interest has lead to signifi cant advances in knowledge regarding the effi cacy and application of exercise therapy following a cancer diagnosis. Given the shift toward patient-centered care and healthcare effi ciency and cost-effectiveness in general, the interest in and scope of exercise-oncology research is projected to further increase over the next two decades. As the fi eld of exercise-oncology enters a new era of research, it is important to overview the current state of science in order to inform and defi ne the critical unanswered questions postulated to have the largest impact on the fi eld and on clinical care.
The purpose of this Opinion article is to provide an overview of the extant literature base together with ongoing/planned studies examining the role of exercise therapy following a cancer diagnosis with a view towards identifying major gaps in the knowledge to ensure continued progress in this emergent fi eld.
Past: Prior research -what do we know?
Several excellent systematic reviews and metaanalyses have extensively evaluated the available literature investigating the role of exercise therapy following a cancer diagnosis [11 -15] . For example, Speck et al. [16] identifi ed a total of 66 ' high-quality ' studies that examined the effects of exercise on 60 different physiological, functional, biological, or psycho-social outcomes in adults with cancer. In brief, the majority of studies were conducted in women with early breast cancer with fewer studies in non-small lung cancer (NSCLC), hematologic malignancies, or involving patients from various types of cancer populations. In general, the exercise interventions closely followed traditional exercise prescription guidelines consisting of supervised or home-based moderate-intensity (50 -75% of baseline maximum heart rate or aerobic capacity), three sessions per week, for 10 -60 minutes per exercise session for 12 -15 weeks. Results indicated that exercise training was associated with signifi cant improvements in muscular strength, aerobic capacity, functional QOL, fatigue, anxiety, and self-esteem. Few adverse events (AEs) were reported. It was concluded that exercise training is a benefi cial adjunct therapy both during and following the completion of adjuvant therapy in adult cancer patients, with low incidence of AEs [16] . The fi ndings and conclusions of Speck et al. [16] are consistent with those of other systematic reviews and meta-analyses [11 -15] .
Clearly, the cancer survivorship continuum encompasses a broad cycle of phases starting with diagnosis and continuing through into therapeutic management, post-treatment recovery (if appropriate), and ultimately palliation/end-of-life. The survivorship continuum provides several distinct opportunities in which to apply exercise therapy as an adjunct to supportive care and/or treatment strategies following a cancer diagnosis. To this end, in this paper we have adapted the Physical Exercise Across the Cancer Experience (PEACE) organizational framework [17] to systematically overview the application of exercise therapy across the survivorship continuum. Specifi cally, we adapted the PEACE framework into three major timepoints [1) pretreatment; 2) during treatment; and 3) post-treatment] encompassing seven categories of outcomes: 1) pretreatment; 2) during treatment -(a) toxicity; 3) during treatment -(b) effi cacy; 4) posttreatment -(a) chronic and late-effects; 5) posttreatment -(b) recurrence and cancer-specifi c mortality; 6) post-treatment -(c) non-cancer mortality; and 7) post-treatment -(d) all-cause mortality. In the following sections, we adopted the PEACE framework to briefl y overview the current state of evidence across each of the PEACE categories incorpo rating evidence from basic, epidemiological, and intervention effi cacy-based science (i.e. T0-T2 research [18]), when available. Review of studies examining the effi cacy of behavioral interventions to increase exercise behavior levels or test behavioral theories in cancer survivors is beyond the scope of this article.
PEACE timepoint 1: Pretreatment
The pretreatment setting could be broadly defi ned as investigating either the association or effi cacy of exercise therapy prior to the initiation of anti-tumor or supportive care therapy in patients with cancer. The primary utility of exercise therapy in this setting focuses on the role of exercise to augment aerobic capacity (i.e. cardiovascular reserve) enabling patients to either undergo or improve recovery from the treatment of choice. Despite the potential applications, a paucity of studies has investigated the role of exercise therapy in this setting; Speck et al. [16] reported that less than 2% of all published studies were conducted in this setting. An illustrative study example in this setting was conducted by Jones et al. [19] reporting that four to six weeks of supervised presurgical moderateto-high intensity aerobic training was associated with signifi cant improvements in aerobic capacity with a low incidence of AEs in 20 lung cancer patients scheduled for pulmonary resection. Two other small single-arm (non-randomized) supervised exercise training studies have reported similar fi ndings in this setting and among this patient cohort [20, 21] . The limited available data suggest that short-term, presurgical exercise training is feasible, well-tolerated, and potentially associated with signifi cant improvements in aerobic capacity.
PEACE timepoint 2: During adjuvant (curative) or palliative therapy
Category two includes all studies examining the application of exercise therapy during anticancer therapy for patients at any stage of disease (curative as well-palliative) as well as exercise during treatment with supportive care agents not given concurrently with anticancer agents. In the present review, we also operationalize the during therapy setting to include two major categories of outcomes: 1) toxicity -the role of exercise to mitigate and/or prevent the anticipated adverse physical and psychological toxicities of cancer therapy; and 2) effi cacy -the role of exercise to interact with the effi cacy of antitumor or supportive care therapies. The level of evidence for both indications is briefl y described herein.
Exercise to prevent and/or mitigate therapy-associated toxicity. Speck et al. [16] reported that 40% of all studies in exercise-oncology were conducted in patients receiving anticancer therapy. The vast majority of studies were conducted in patients with earlystage disease, predominantly women with breast cancer, receiving conventional cytotoxic therapies such as chemotherapy, radiotherapy, or androgen deprivation therapy (in the case of prostate cancer patients). Briefl y, results indicated that supervised exercise training following traditional guidelines [i.e. aerobic training (3 d/wk, for 30 -45 min per session, at 50 -75% of age-predicted heart rate maximum or baseline aerobic capacity for 12 -15 weeks) or resistance training (3 d/wk, 10 exercises, at 60 -70% of one-repetition maximum)] was associated with improvements in measures of aerobic capacity, upper and lower extremity muscle strength, functional QOL, and several other psychological outcomes (e.g. anxiety, self-esteem), with a low incidence of AEs. There was, however, considerable heterogeneity in study methodology including patient population, treatment type, and outcome assessments making data interpretation challenging. Overall, the current literature base indicates that supervised exercise therapy is safe and feasible and associated with signifi cant improvements in select outcomes in patients with early-stage disease receiving conventional cytotoxic adjuvant therapy. The present results are not generalizable to patients with advanced disease, those receiving novel antitumor therapies (e.g. small molecule inhibitors), or those with early-stage disease not diagnosed with breast or prostate cancer.
Few studies to date have examined the effi cacy of exercise therapy during cancer therapy beyond common physical and psychological outcomes, as described above. Of importance, however, several investigators have utilized mouse models to examine whether exercise attenuates chemotherapy-induced cardiac dysfunction, a common adverse side effect observed in a broad range of malignancies [22] . In a recent review of published studies, Scott et al. [23] concluded that both acute and chronic (repeated) moderate-intensity voluntary wheel exercise preserved cardiac function in mice receiving doxorubicin chemotherapy. In the only clinical study to date, Haykowsky et al. [24] found that supervised aerobic training did not attenuate adjuvant trastuzumabinduced left ventricular dilation or prevent declines in ejection fraction in 17 women with HER-2 positive early breast cancer, although adherence to the exercise intervention was less than optimal and no control group (i.e. trastuzumab-only) was included.
Exercise to alter treatment effi cacy. The potential interaction between exercise and therapeutic efficacy of anticancer or supportive care agents has received minimal attention. In the only preclinical study to date, Jones et al. [25] found that tumor growth was comparable in female mice bearing human breast cancer xenografts treated with doxorubicin alone or doxorubicin plus exercise training. In the only patient study to date, Courneya et al. [26] reported that supervised resistance training but not aerobic training increased adjuvant chemotherapy completion rates, in comparison to a usual care group, in 242 operable breast cancer patients. While intriguing, the clinical importance of the fi ndings of Jones et al. and Courneya et al. remain to be determined.
PEACE timepoint 3: Post-adjuvant therapy
Improvements in early detection together with more effective adjuvant treatment has led to signifi cant cancer-specifi c survival gains for individuals diagnosed with cancer [27] . It is becoming increasingly evident, however, that improved survival comes at the price of enduring both chronic (present during treatment and enduring) and late-effects (not present at the end of treatment with late manifestation) of therapy. Here, we also operationalize the posttreatment setting to include four major categories of outcomes: 1) chronic and late-effects -the role of exercise to mitigate, prevent, and/or treat the anticipated adverse physical and psychological chronic and late-effects of primary adjuvant therapy; 2) recurrence and cancer-specifi c mortality -whether exercise inhibits/alters cancer progression; 3) non-cancer mortality -the role of exercise to reduce the risk of competing causes of mortality in cancer patients; and 4) all-cause mortality -role of exercise to improve overall survival.
Chronic or treatment late-effects. Speck et al. [16] reported that 60% of all studies in exercise-oncology were conducted in the post-adjuvant therapy setting. Similar to the during therapy setting, the vast majority of studies were conducted in women with breast cancer. In brief, results indicated that supervised exercise training following traditional guidelines was associated with improvements in measures of aerobic capacity, upper and lower extremity muscle strength, overall QOL, fatigue, and several other psychological outcomes (e.g. mood disturbance, confusion), with a low incidence of AEs. Again, considerable heterogeneity was evident in patient population, prior treatment, and outcome assessments. Overall, the current literature base supports the conclusion that supervised exercise therapy is a safe and feasible intervention associated with signifi cant improvements in select therapy-associated chronic and late-effects.
Recurrence (biomarkers) and cancer-specifi c mortality.
A major question of interest in exercise-oncology research is whether exercise therapy alters cancer progression following a cancer diagnosis. Data from randomized trials are not currently available; however, a growing number of epidemiological studies have examined the relationship between self-reported exercise behavior or measures of functional capacity/ aerobic capacity (measured after the cancer diagnosis), and prognosis (i.e. recurrence, cancer-specifi c mortality, non-cancer mortality, and all-cause mortality) in persons diagnosed with cancer. For a detailed overview of this research the reader is referred to recent reviews [28, 29] . Briefl y, in breast cancer, two studies found that higher levels of exercise were associated with signifi cant reductions in cancer-specifi c mortality; all studies in colorectal or prostate cancer reported a signifi cant inverse relationship between exercise and cancer-specifi c mortality or progression.
Rodent models of cancer also provide a wellestablished method to investigate the effects of exercise on tumor progression and metastasis, although surprisingly few studies have been published to date. In a recent review, Betof et al. [29] identifi ed a total of 14 animal studies investigating the effects of endurance exercise on tumor endpoints in a variety of different model systems. Overall, the authors concluded that effects of exercise on tumor growth and metastasis were inconclusive due to the low number of studies and considerable heterogeneity between studies.
To gain insight into how exercise therapy may modulate cancer-specifi c outcomes in cancer patients several research groups have started to investigate the effi cacy of exercise therapy to alter circulating levels of specifi c biomarkers postulated to mediate the exercise-cancer prognosis relationship. Two reviews of this research were recently published [28, 29] . In brief, approximately 24 studies to date have investigated the effects of structured exercise training on changes in circulating concentrations of hostrelated factors, with most studies focusing on the insulin-glucose axis and immune surveillance. Based on the current evidence, there are no clear conclusions regarding the effi cacy of exercise therapy on hostrelated mechanisms.
Non-cancer mortality. Therapy-induced chronic and late effects are not only an important cause of morbidity in cancer patients but they also contribute to increased risk of non-cancer competing mortality, particularly cardiovascular disease (CVD) [30 -35] . Indeed, in certain cancer populations (e.g. breast, prostate), CVD is not only the predominant cause of mortality but these patient cohorts have excess CVD events/mortality relative to age-sex-matched individuals without a history of cancer [30, 33] . To our knowledge, no studies to date have examined either the effects of exercise therapy or the relationship between exercise and CVD-related events in cancer patients.
All-cause mortality. To our knowledge, there are no published studies of RCTs testing the effects of exercise on all-cause mortality among cancer survivors. Approximately 16 epidemiological studies to date have examined the relationship between self-reported exercise behavior or aerobic capacity/functional capacity and all-cause mortality in patients with colorectal, breast, prostate, and lung cancer. There is relatively consistent data indicating that higher levels of exercise are associated with reductions in the risk of death from any cause, with eight studies reporting signifi cant reductions in risk [28] . There were also consistent inverse relationships between higher levels of aerobic capacity or functional capacity (i.e. six minute walk distance) and risk of death from any cause. For example, peak oxygen consumption (VO 2peak ), the gold standard assessment of aerobic capacity, was a strong independent predictor of death in 398 surgical candidates with NSCLC after adjustment for performance status, age, gender, and pulmonary function [36] .
Present: Ongoing research -what are we currently doing?
Since the early work of Winningham and MacVicar, there have been signifi cant leaps in knowledge about the role and effi cacy of exercise therapy following a cancer diagnosis. On the basis of current knowledge, several international agencies have published cancerspecifi c exercise guidelines for cancer patients both during and following the completion of primary therapy [37 -40] . We argue that the current evidence base has addressed several fundamental questions providing a solid platform to launch the next generation of trials. To this end, we performed a systematic review of all ongoing exercise trials in adult cancer patients across the cancer survivorship con-tinuum registered in Clinical Trials.Gov (as of 1 August 2012) and the International Standard Randomized Controlled Trial Number Register (as of 9 October 2012). A total of 82 independent clinical studies were identifi ed (Table I) .
To summarize, by the adapted PEACE framework for major outcomes, studies were categorized as follows: 1) pretreatment (n ϭ 5; 6%); 2) during treatment -(a) toxicity (n ϭ 42; 51%); 3) during treatment -(b) effi cacy (n ϭ 0; 0%); 4) posttreatment -(a) chronic and late-effects (n ϭ 29; 35%); 5) post treatment -(b) recurrence and cancerspecifi c mortality (n ϭ 5; 6%); 6) post-treatment -(c) non-cancer mortality (n ϭ 0; 0%); and (7) posttreatment -(d) all-cause mortality (n ϭ 1; 2%). Regarding study characteristics, 53 (65%) and 22 (27%) studies are two-arm RCTs or Ͼ 2 arm-RCTs, respectively. The vast majority of studies are recruiting patients with early breast cancer (n ϭ 32; 40%), with a smaller number of studies recruiting patients with prostate (n ϭ 9, 11%), colorectal (n ϭ 6, 8%), lung cancer (n ϭ 6, 8%), with the remainder recruiting patients of various cancer diagnoses. The average sample size is 171 (range 10 -1070). With respect to the exercise intervention characteristics, the majority of studies are assessing aerobic training alone (n ϭ 20; 25%), combined aerobic and resistance training (n ϭ 21, 25%), different exercise modalities or doses 11 (14%). Or exercise training in combination with a non-exercise intervention (e.g. relaxation, nutrition, stress management) (n ϭ 9; 11%). In terms of setting, 29 (35%), 23 (28%), and 21 (26%) are being conducted in a supervised, home-based, or supervised and home-based setting, respectively.
Consistent with prior work, in general, the exercise interventions followed standard exercise prescription guidelines consisting of exercise training three days/week at a moderate intensity (limited information was provided on the specifi c components of the planned exercise prescriptions in the majority of trials). Across all studies, there were a total of approximately 51 different primary endpoints, although in two-thirds of studies, QOL, fatigue, or physical functioning was the primary endpoint. A brief summary of ongoing studies by PEACE framework category is provided in Table I and briefl y summarized herein.
PEACE timepoint 1: Pretreatment
A total of fi ve studies are currently being conducted in this setting. The majority of these are focusing on the effects of aerobic training to improve aerobic capacity/functional performance status in surgical candidates with colon, lung, or liver cancer. One study is examining the effect of presurgical exercise training to alter tumor biology (as assessed by Ki-67).
PEACE timepoint 2: During treatment
All studies in this setting are investigating the effects of exercise therapy to mitigate the toxicity of anticancer therapy; no studies are assessing the potential interaction between exercise and treatment effi cacy. The majority of studies continue to evaluate the efficacy of exercise on aerobic capacity, measures of physical functioning, and PROs, generally in women with early breast cancer receiving adjuvant therapy. There are, however, ongoing studies examining the effects of exercise on prevention and/or mitigation of adverse toxicities associated with specifi c treatments. For example, arthralgias associated with aromatase inhibitors or neuropathy associated with use of taxane-based chemotherapy, and cognitive dysfunction associated with chemotherapy. There continues to be a signifi cant interest in the effi cacy of exercise, particularly resistance training, to offset the physiological side effects of androgen deprivation therapy in men with prostate cancer. At least fi ve studies are underway examining the feasibility and effi cacy of exercise in patients with advanced disease. Most studies are conducting two-arm RCTs, although a number are comparing different exercise modalities or intensities as well as effi cacy of exercise relative to a non-exercise intervention such as stress management or nutritional supplementation.
PEACE timepoint 3: Post-treatment
Studies in this setting are, in general, evaluating the effects of exercise on attenuation/treatment of chronic and treatment late-effects, with fewer studies examining recurrence or cancer-specifi c mortality or all-cause mortality. No studies are investigating the effects on non-cancer related causes of mortality. Concerning chronic and lateeffects research, the majority of studies continue to study women with early breast cancer following the completion of conventional adjuvant therapy on endpoints such as functional capacity, body composition, and fatigue. However, several relatively novel endpoints are also evident including risk of falls, neurocognitive function, bone health, and sexual function. Several studies are also being conducted in prostate, lung, colorectal, endometrial, and head and neck cancer survivors as well as those following completion of hematopoietic cell transplantation. As in the during therapy category, most studies are conducting two-arm RCTs (testing the effects of exercise following traditional exercise prescription guidelines), although there are studies comparing different exercise modalities or intensities as well as effi cacy of exercise relative to a non-exercise intervention such as stress management or nutritional supplementation, or studies using exercise as a means to facilitate weight loss.
Five studies are currently being conducted examining the effects of exercise on recurrence (biomarkers) and cancer-specifi c mortality. Specifi cally, in three of these studies, the primary endpoint is disease-free survival or a plasma biomarker associated with recurrence risk is primary. The three clinical outcome trials are adequately powered for survival assessing either the effi cacy of a combination of home and supervised aerobic exercise either alone or in combination with dietary advice or antiangiogenic therapy. With the exception of the latter, all studies are currently being conducted in cancer patients following the completion of primary adjuvant therapy. Finally, one study, a randomized trial examining the combined effects of exercise with relaxation training in patients undergoing allogenic stem cell transplantation, the primary outcome is overall survival.
Future: Gaps in knowledge -where do we need to go?
Prior and ongoing studies have created considerable momentum that will continue to drive forward the fi eld of exercise-oncology research over the next decade. However, in conjunction with such efforts, it is also important to take the opportunity to pause and critically review the current (and forthcoming) literature base to ensure that we are addressing the fundamental questions as well as potential paradigm-changing questions that will signifi cantly contribute to the long-term goals of improving exercise-oncology research and care for cancer survivors. The major gaps in knowledge and suggested future directions are presented in Table II , organized by PEACE framework category.
Other methodological issues
In addition to the major identifi ed knowledge gaps, review of the literature raised several additional methodological issues that apply to exercise-oncology research across all PEACE categories. These include but are not exclusive to the following:
Nature and type of control groups. A somewhat unique feature to clinical trials involving behavioral interventions, and particularly exercise interventions, is the nature and type of control groups. Clearly, in contrast to pharmacological interventions, it is not possible to blind participants to whether they are receiving exercise therapy or not. In addition, there is no established or widely accepted standard of care for exercise therapy (in terms of dose, timing, or setting) in the oncology setting. Furthermore, unlike many European countries, exercise rehabilitation or even exercise advice is not considered part of standard oncology care in North America. As such, the type and nature of ' control ' groups in exerciseoncology trials is an important consideration. Prior and forthcoming trials in the fi eld have essentially adopted three different types of control groups: 1) a non-intervention condition (participants assigned to this group receive no intervention). Advantages of this control group include comparison of exercise training to a ' true ' control or ' usual care ' control (at least in North America), which minimizes the risk of exercise contamination (initiation of exercise in participants randomized to usual care) and dilution of the exercise ' effect ' (if control participants are offered some type of intervention this could potentially minimize any between group differences on some study-related outcomes). Disadvantages of this approach include potential problems with participant recruitment (patients interested in exercise intervention studies may not motivated to participate in a study with potential randomization to a non-intervention control group), adherence/contamination (some patients may spontaneously initiate exercise training), and lost-to-follow-up; 2) a wait-list group (participants receive an exercise program at the end of the intervention study). Advantages of this approach include potentially enhanced recruitment rates and minimization of exercise contamination and lost-to-follow. However, this approach may not be appropriate for all exerciseoncology settings (e.g. in patients with advanced disease). In addition, participants may not be willing to wait until the end of the study to initiate exercise training; and 3) attention-control groups (participants receive either exercise materials, health information, or non-exercise intervention such as progressive stretching). Again, such approaches may enhance recruitment rates and minimization of exercise contamination and lost-to-follow (all patients receive an ' intervention ' ). Disadvantages include that there is no true attention-control that mimics exercise training which may impact adherence/ contamination, and lost-to-follow-up rates. Selection of the type and nature of the control group needs to be based on consideration of several key methodological factors including: 1) study primary endpoint; 2) participant recruitment, attrition, and adherence; 3) study setting; and 4) existing evidence base pertaining to the study question.
Safety of exercise testing and exercise training . The reporting of AEs in exercise-oncology trials is less Table II . Gaps in knowledge based on PEACE framework timepoint. PEACE framework timepoint 1. Pretreatment · Adequately powered trials to determine the effects of presurgical exercise training on surgical complications and recovery in patients undergoing extensive surgical resections for operable disease · Determine whether presurgical exercise training improves post-surgical recovery and time to initiation of adjuvant therapy · Determine the feasibility, safety, and effi cacy of exercise training in the window between the completion of induction or neoadjuvant therapy and surgical resection (to lower d to surgery or improve surgical recovery) · Elucidate the effects of exercise training on changes in tumor phenotype in conjunction with procurement of circulating biomarkers by conducting presurgical ' window of opportunity ' studies · Test whether exercise training delivered before hematopoietic cell transplantation improves posttransplant outcomes 2. During therapy a. Toxicity · Elucidate the effects and mechanisms of exercise training on common but currently understudied physiological toxicities (e.g. cardiotoxicity, peripheral neuropathy, thrombosis, bone loss) of conventional and forthcoming anticancer therapies · Identify the factors that predict response to exercise for prevention and/or treatment of physiological and psychological toxicities of treatment · Elucidate the optimal dose, type, timing, and length of exercise to prevent and/or mitigate common cancer therapy-related toxicities, including whether these vary by cancer, treatment, or host factors · Determine the effects of exercise on treatment tolerability, completion rates (adherence), and dose-modifi cation · Determine the effects of exercise on fi scal outcomes such as return to work, capacity for caregiving for children/aging parents, hospital visits, and comorbidity medication requirements 2. During therapy b. Therapy effi cacy · Elucidate the differential effects and mechanisms of exercise training on the effi cacy of conventional and forthcoming anticancer therapies adopting a translational bench-to-bedside approach · Elucidate the effects and mechanisms of exercise training on the effi cacy of conventional and forthcoming supportive care therapies (e.g. bisphosphonates, antiemetic, various growth factors) adopting translational bench-to-bedside approaches 3. Post-therapy a. Chronic & late effects · Elucidate the effects and mechanisms of exercise training to prevent and/or treat common and emerging chronic and late-effects of treatment (e.g. cardiotoxicity, peripheral neuropathy, thrombosis, bone turnover) · Identify the factors (e.g. treatment type, exercise history, other host factors) that predict response to exercise for prevention and/or treatment of physiological and psychological chronic or late-effects · Elucidate the optimal dose, type, timing, and length of exercise to prevent and/or mitigate chronic or late effects of treatment, including whether these vary by cancer, treatment, or host factors · Explore the relationship between cancer-treatment chronic and late-effects and cancer progression as well as the role of exercise to modify this relationship b. Recurrence & cancer-specifi c mortality · Expand the number of large-scale studies assessing both self-reported and/or objective measures of exercise exposure with long-term follow-up and adequate event rates in understudied cancer types · More studies determining the differential association between exercise and prognosis as a function of tumor phenotype/gene expression and host-related factors · Elucidation of the optimal dose of exercise to inhibit tumor progression/metastasis in mouse models of solid tumors to guide the dose of exercise to be tested in phase II randomized trials · Determine the optimal dose, type, timing, and length of exercise to infl uence tumor progression/metastasis in humans, including whether these vary by cancer, treatment, or host factors c. Non-cancer mortality · Expand the number of large-scale studies assessing both self-reported and/or objective measures of exercise exposure with long-term follow-up and adequate event rates for a variety of diseases commonly comorbid with cancer/competing causes of death in survivors (Continued) Acta Oncol Downloaded from informahealthcare.com by 167.94.2.15 on 11/20/14
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PEACE framework timepoint
· More studies determining the differential association between exercise and non-cancer related mortality as a function of cancer type, prior treatment, host-related factors, and concomitant morbidities · Determine the optimal dose, type, timing, and length of exercise needed to infl uence noncancer mortality, including whether prescribing exercise suffi cient to affect a pathway common to multiple comorbidities (e.g. infl ammation) might have multiplicative and not just additive effects on non-cancer mortality · Utilize mouse models to determine the effects and mechanisms of exercise on non-cancer related morbidity and mortality in cancer mouse models d. All-cause mortality · A greater number of large-scale epidemiological studies assessing both self-reported and/or objective measures of exercise exposure with long-term follow-up on cause-specifi c mortality as well as overall mortality in a broad range of cancer populations · Determine the optimal dose, type, timing, and length of exercise needed to infl uence all-cause mortality, including how this differs by cancer, treatment, or host factors.
PEACE, Physical Exercise Across the Cancer Experience.
than optimal [41] . RCTs need to be carefully designed to fully evaluate the harms (e.g. treatmentand exercise-related) and benefi ts of exercise rehabilitation using standardized outcomes and AE monitoring and reporting to determine the risk-to-benefi t ratio in the oncology setting.
Standardized endpoints. There is considerable variation in the outcome assessments used to evaluate the effi cacy of exercise therapy on changes in physiologic and PROs in cancer patients. In terms of the latter, there is currently no accepted gold standard assessment of QOL or fatigue in oncology. However, investigators should strive to adopt global QOL scales (e.g. SF-36; FACT system) and newly-developed tools from the Patient-Reported Outcomes Measurement Information System (PROMIS) project as well as the establish Common Terminology Criteria for Adverse Events (CTCAE) for monitoring and reporting of AEs in randomized trials wherever appropriate. In contrast, cardiopulmonary exercise testing with direct gas exchange measurement is considered the gold standard assessment of cardiorespiratory fi tness in humans and is the preferred method of testing in the majority of oncology settings [42, 43] .
Study methodology homogeneity . Further trials should strive to restrict study recruitment to relatively homogenous sub-groups of patients in terms of cancer site (or histological sub-type) and current or prior anticancer therapy. Such studies will facilitate data synthesis and interpretation as well as comparative effectiveness research. Nevertheless, the level of study sample homogeneity is also somewhat dependent on the primary study question. For example, for a specifi c treatment-related or tumor-associated outcome, homogenous groups are critical. However, for more general outcomes, such as comparison of the QOL response to exercise across different types of cancer or treatment, more heterogeneous samples are of course required.
Designing for dissemination and implementation. As exercise-oncology trials progress and mechanistic questions are answered, it will be important for this research to progress toward T3 research using study designs that identify best practices for disseminating appropriate and effective exercise interventions to all survivors. While discussion of this topic is beyond the scope of this review, it is important to note that the dissemination potential will be far greater if T0 -T2 research discussed here is designed with consideration of dissemination as the ultimate goal.
Conclusion
When the fi rst studies investigating the effi cacy of aerobic training were completed almost a quarter of a century ago, not even the most fervent of exercise advocates would have predicted the scope, clinical and patient interest, and impact exercise has made in the oncology setting. Signifi cant progress has been made in these 25 years; however, it is time to launch the fi eld into the next generation of research by addressing the major identifi ed gaps in knowledge. Addressing these questions will ensure continued progress in this emergent fi eld that, in turn, will contribute to the ultimate goal of improving the quantity and quality of life of individuals diagnosed with cancer.
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